A New Generation of Drugs Targeting PD-1/PD-L1 Takes Shape in Oncology
June 8th 2020Over the past decade, immunotherapy has established itself as one of the pillars of cancer treatment, thanks in large part to the success of monoclonal antibodies that target the immune checkpoint protein PD-1 or its main ligand, PD-L1.
A New Generation of Drugs Targeting PD-1/PD-L1 Takes Shape in Oncology
June 8th 2020Over the past decade, immunotherapy has established itself as one of the pillars of cancer treatment, thanks in large part to the success of monoclonal antibodies that target the immune checkpoint protein PD-1 or its main ligand, PD-L1.
Sequencing Options Expand for Patients With HER2+ MBC and Brain Metastases
June 5th 2020Collectively, there are more options than ever in the space of HER2-positive breast cancer brain metastases, a significant advance for our hundreds and thousands of patients facing this challenging disease.
Experts Provide Tips on Harnessing MRD to Guide ALL Therapy
June 4th 2020During a recent OncLive Peer Exchange®, a panel of experts in adult and pediatric leukemia provided insight on how they use minimal or measurable residual disease (MRD) to guide treatment decisions, including transplantation and choice of therapy in patients who demonstrate MRD positivity after induction and first- and subsequent-line therapies.
Pandemic Poses a Crucial Moment for Science and the Public Trust
June 2nd 2020At this moment, we should consider what it will take for the scientific community as a collective entity to self-regulate far more forcefully so that the actions of a limited number of its members do not squander the well-deserved awakening of public trust in the entire scientific enterprise.